Company Analysis

Metagenomi Therapeutics, Inc. (MGX)

Nasdaq: MGX · Biological Products, (No Diagnostic Substances) · Emeryville, CA · filing with the SEC since 2019
Grade4.6
◀ Past 4.4● Present 4.9▶ Future 4.4
2 est.

Who runs Metagenomi Therapeutics, Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Irish Jian
President and Chief Executive Officer. First filing Feb 2024, latest Sep 10, 2026, 6 filings in all.
Officers reporting now
4
of 8 people with a filing in the last fifteen months
Directors reporting now
4
13 people on the record since 2024
Officerssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Irish JianPresident and Chief Executive OfficerFeb 2024Sep 10, 20264 · $0.00
Wapnick PamelaChief Financial OfficerFeb 2024Sep 10, 20264 · $0.00
Wein MatthewTitle: General Counsel, Compliance Officer and Corporate SecretaryFeb 2024Sep 10, 20264 · $0.00
Thomas Brian C.Chief Executive OfficerFeb 2024Dec 8, 20251 · $0.00
Directorssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameRoleFirst filingLatest filingSales, 12 months
Reid LaurencedirectorAug 2025Sep 11, 2026none
Bjerkholt EricdirectorJan 2025Jun 11, 2026none
Dere Willard HdirectorFeb 2024Jun 11, 2026none
Eckhardt JuergendirectorFeb 2024Jun 11, 2026none
Earlier names on the record10, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton MGX · research, not advice